Kazia Therapeutics Limited
KZIA
$6.75
$0.172.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 21,350.00% | 20,133.33% | 18,883.33% | 18,966.67% | -- |
| Total Revenue | 274,583.33% | 273,366.67% | 272,116.67% | 271,933.33% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 274,583.33% | 273,366.67% | 272,116.67% | 271,933.33% | -- |
| SG&A Expenses | 58.09% | 57.12% | 54.11% | 38.50% | 21.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.61% | 41.86% | 25.08% | -2.58% | -27.24% |
| Operating Income | -47.85% | -30.55% | -15.04% | 7.37% | 27.24% |
| Income Before Tax | -78.49% | -50.80% | -27.38% | 10.71% | 40.29% |
| Income Tax Expenses | 0.78% | 1.00% | 2.58% | -14.44% | -40.26% |
| Earnings from Continuing Operations | -79.86% | -51.58% | -27.77% | 10.96% | 40.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.86% | -51.58% | -27.77% | 10.96% | 40.88% |
| EBIT | -47.85% | -30.55% | -15.04% | 7.37% | 27.24% |
| EBITDA | -53.02% | -33.51% | -16.52% | 7.65% | 29.05% |
| EPS Basic | -27.75% | 3.53% | 21.91% | 47.67% | 64.51% |
| Normalized Basic EPS | -7.07% | 15.60% | 30.20% | 45.32% | 56.25% |
| EPS Diluted | -27.75% | 3.53% | 21.91% | 47.67% | 64.51% |
| Normalized Diluted EPS | -7.07% | 15.60% | 30.20% | 45.32% | 56.25% |
| Average Basic Shares Outstanding | 54.03% | 49.18% | 43.09% | 53.00% | 66.11% |
| Average Diluted Shares Outstanding | 64.71% | 60.00% | 53.85% | 60.87% | 70.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |